TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37758967

Group type: EXPERIMENTAL
Intervention: Pharmacist evaluation and monitoring based on the implementation of a recently published checklist including evaluation of appropriateness of DOAC, need for affordability assistance, three pharmacist-initiated telephone consultations, access to a DOAC hotline, documented hand-off to continuity provider, and monitoring of follow-up laboratory tests.
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Pharmacist evaluation and monitoring based on the implementation of a recently published checklist.
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Coupons and assistance to increase the affordability of DOACs.
Number of subjects: 561

Group type: COMPARATOR
Intervention: Control group (standard care without pharmacist intervention).
Number of subjects: 561
Study: 37759037

Group type: EXPERIMENTAL
Intervention: Single-session intervention including a visuospatial task delivered by trained maternity clinicians.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Attention-placebo control group
Number of subjects: 146
Study: 37759099

Group type: EXPERIMENTAL
Intervention: Biologic therapy achieving PASI90
Number of subjects: 687
Study: 37759148

Group type: EXPERIMENTAL
Intervention: INOSEL program (Integrative Nursing and Omaha System)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 69
Study: 37759174

Group type: EXPERIMENTAL
Intervention: PaGES Index (Participant-Generated Experience and Satisfaction Index)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PaGES Index (before and after birth)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation (qMOLI)
Number of subjects: 68
Study: 37759212

Group type: EXPERIMENTAL
Intervention: Supervised group-based walking intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-supervised individual-based walking intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37759268

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion
Number of subjects: 181
Study: 37759324

Group type: EXPERIMENTAL
Intervention: Personalized multimodal treatment (individualized physical exercise program combined with individualized nutritional therapy) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physiotherapy for 12 weeks
Number of subjects: 0
Study: 37759330

Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 284
Study: 37759489

Group type: EXPERIMENTAL
Intervention: PARPi-niraparib therapy
Number of subjects: 31
Study: 37760514

Group type: EXPERIMENTAL
Intervention: Pharmacist and diabetologist interventions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ONCODIAB follow-up
Number of subjects: 102
Study: 37762777

Group type: EXPERIMENTAL
Intervention: Symptom questionnaire (65-item WISE symptom questionnaire)
Number of subjects: 916
Study: 37764667

Group type: EXPERIMENTAL
Intervention: Oral probiotic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37764780

Group type: EXPERIMENTAL
Intervention: 15-week telephone-based lifestyle intervention (n = 27)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 40
Study: 37764840

Group type: EXPERIMENTAL
Intervention: Whole milk-based goat milk formula (GMF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Whey-based cow milk formula (CMF)
Number of subjects: 64
Study: 37765023

Group type: EXPERIMENTAL
Intervention: Prednisolone + Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Romiplostim
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose Dexamethasone (HD-DXM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltrombopag following HD-DXM
Number of subjects: 0
Study: 37765154

Group type: EXPERIMENTAL
Intervention: Continuous levobupivacaine wound infiltration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bolus levobupivacaine wound infiltration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac analgesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCA
Number of subjects: 120
Study: 37766218

Group type: EXPERIMENTAL
Intervention: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS) for characterising HIV-1 DNA drug resistance mutations (DRMs).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS).
Number of subjects: 0
Study: 37766505

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART (DTG)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard-of-care treatment (SOC)
Number of subjects: 229
Study: 37766731

Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine (15 g/day divided into 3 intakes for 30 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine
Number of subjects: 19
Study: 37766747

Group type: EXPERIMENTAL
Intervention: Nature-based intervention (guided nature walks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise-based intervention (group exercise)
Number of subjects: 0
Study: 37766882

Group type: EXPERIMENTAL
Intervention: Food insecurity intervention (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 37766884

Group type: EXPERIMENTAL
Intervention: MediYoga (performed for one hour/week over a 12-week period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 37766922

Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 12 months
Number of subjects: 78
Study: 37767191

Group type: EXPERIMENTAL
Intervention: Anlotinib maintenance treatment
Number of subjects: 49
Study: 37767195

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with a target LDL-C level of 50-70 mg/dL
Number of subjects: 4400

Group type: COMPARATOR
Intervention: High-intensity statin treatment
Number of subjects: 4400
Study: 37767632

Group type: EXPERIMENTAL
Intervention: Repeated Shockwaves Lithotripsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37767674

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6263

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 37767823

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham bright light therapy
Number of subjects: 14
Study: 37767993

Group type: EXPERIMENTAL
Intervention: Intervention 1 (TSP-9 results provided)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Intervention 2 (option to order TSP-9 results)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (no TSP-9 results)
Number of subjects: 259
Study: 37768018

Group type: EXPERIMENTAL
Intervention: Sex chromosome dosage (SCD)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Longitudinal measures from karyotypes (XXX, XXY, XYY, XXYY)
Number of subjects: 177
Study: 37768273

Group type: EXPERIMENTAL
Intervention: Choriocapillaris flow signal deficits (FD%) in early AMD (N = 122)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Choriocapillaris flow signal deficits (FD%) in intermediate AMD (N = 92)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Choriocapillaris flow signal deficits (FD%) in normal eyes (N = 196)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Rod-mediated dark adaptation (RMDA)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Choriocapillaris FD% in eyes with subretinal drusenoid deposits (SDD) (N = 87)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Choriocapillaris FD% in eyes without subretinal drusenoid deposits (SDD) (N = 323)
Number of subjects: 410
Study: 37768317

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (40 mg/kg daily, RIF40)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard-dose rifampicin (10 mg/kg daily, RIF10)
Number of subjects: 25
Study: 37768344

Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Combined Training (COMB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 109
Study: 37768427

Group type: EXPERIMENTAL
Intervention: PrEP disclosure and social support
Number of subjects: 451

Group type: COMPARATOR
Intervention: PrEP use
Number of subjects: 451
Study: 37768628

Group type: EXPERIMENTAL
Intervention: Adapted-Coping With Stress course (A-CWS)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 410
Study: 37768631

Group type: EXPERIMENTAL
Intervention: 4-week meditation app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 37768633

Group type: EXPERIMENTAL
Intervention: StriveWeekly web-based intervention
Number of subjects: 0
Study: 37768658

Group type: EXPERIMENTAL
Intervention: Tiragolumab (2 mg escalating to 1200 mg) in phase 1a and combination with Atezolizumab (1200 mg every 3 weeks) in phase 1b
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of Tiragolumab plus Atezolizumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Tiragolumab alone
Number of subjects: 73
Study: 37768670

Group type: EXPERIMENTAL
Intervention: CRT plus lapatinib (1500 mg per day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: CRT plus placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: CRT plus lapatinib
Number of subjects: 142
Study: 37768671

Group type: EXPERIMENTAL
Intervention: Eplontersen (45 mg every 4 weeks; n=144)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (historical control; n=60)
Number of subjects: 168
Study: 37768713

Group type: EXPERIMENTAL
Intervention: Active Brains (AB)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 260
Study: 37768719

Group type: EXPERIMENTAL
Intervention: Conventional training group (lecture-based training)
Number of subjects: 29

Group type: COMPARATOR
Intervention: VR-based training group (VR-based ALS serious game module)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Preference survey
Number of subjects: 29
Study: 37768980

Group type: EXPERIMENTAL
Intervention: Healthy eating and stress management program
Number of subjects: 107
Study: 37769113

Group type: EXPERIMENTAL
Intervention: Larotrectinib 100 mg orally twice daily
Number of subjects: 36
Study: 37769182

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 37769181

Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks, respectively.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide combination treatment.
Number of subjects: 215
Study: 37769187

Group type: EXPERIMENTAL
Intervention: Monofocal IOL implantation
Number of subjects: 29
Study: 37769308

Group type: EXPERIMENTAL
Intervention: Occipital nerve block
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care (oral 650 mg acetaminophen and 200 mg caffeine)
Number of subjects: 62
Study: 37769311

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 37769314

Group type: EXPERIMENTAL
Intervention: Mean BP below 130/80 mm Hg
Number of subjects: 2096

Group type: COMPARATOR
Intervention: Mean BP 130-139/80-89 mm Hg
Number of subjects: 2096
Study: 37769319

Group type: COMPARATOR
Intervention: Quartile 1 (least disadvantaged)
Number of subjects: 8983

Group type: EXPERIMENTAL
Intervention: Quartile 4 (most disadvantaged)
Number of subjects: 8983

Group type: EXPERIMENTAL
Intervention: Quartile 2
Number of subjects: 8983

Group type: EXPERIMENTAL
Intervention: Quartile 3
Number of subjects: 8983
Study: 37769369

Group type: EXPERIMENTAL
Intervention: modified ketogenic diet (mKD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo diet (PD)
Number of subjects: 20
Study: 37769428

Group type: EXPERIMENTAL
Intervention: Inebilizumab 300 mg IV on Days 1 and 15
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 37769429

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (2 or 3 doses after ≥1 month of subcutaneous ofatumumab 20 mg/month)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (3 doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (2 doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine (for patients aged <40 years without previous anti-CD20 therapy)
Number of subjects: 26
Study: 37769545

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 287
Study: 37769610

Group type: EXPERIMENTAL
Intervention: Cardiologists interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Internal medicine residents interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Medical students (years 4-6) interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Medical students (years 1-3) interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Participants with prior experience interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Participants with no prior experience interpreting SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: First five interpreted SL-ECGs
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Last five interpreted SL-ECGs
Number of subjects: 450

Group type: COMPARATOR
Intervention: Comparison of accuracy between five smart devices
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Apple Watch SL-ECGs
Number of subjects: 450
Study: 37769619

Group type: EXPERIMENTAL
Intervention: Ad hoc CTO PCI
Number of subjects: 899

Group type: COMPARATOR
Intervention: Control group (non-ad hoc CTO PCI)
Number of subjects: 899
Study: 37770111

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37770120

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil
Number of subjects: 170

Group type: COMPARATOR
Intervention: Oral/intravenous opioids
Number of subjects: 170
Study: 37770132

Group type: EXPERIMENTAL
Intervention: Noninvasive therapies (silver diamine fluoride, self-assembling peptide P)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Noninvasive therapies (including self-assembling peptide P)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios with noninvasive therapies
Number of subjects: 1000
Study: 37770186

Group type: EXPERIMENTAL
Intervention: Slow wave sleep (SWS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cognitive reserve (CR) proxies
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Higher cognitive reserve (CR)
Number of subjects: 135
Study: 37770267

Group type: EXPERIMENTAL
Intervention: SEARCH algorithm for post-PE diagnoses
Number of subjects: 150
Study: 37770273

Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with apatinib and camrelizumab
Number of subjects: 0
Study: 37770278

Group type: EXPERIMENTAL
Intervention: Short screening for CRF using five items at high frequency during therapy and lower frequency during post-treatment phase for 18 months
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Online assessments of psychological, socio-demographical, or medical factors that may exacerbate CRF
Number of subjects: 300
Study: 37770277

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 46
Study: 37770309

Group type: EXPERIMENTAL
Intervention: Delayed-release/extended-release methylphenidate (DR/ER-MPH)
Number of subjects: 395
Study: 37770476

Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤5h)
Number of subjects: 445966

Group type: EXPERIMENTAL
Intervention: Long sleep duration (≥10h)
Number of subjects: 445966

Group type: EXPERIMENTAL
Intervention: SNP-based heritability for both sleep traits
Number of subjects: 445966

Group type: EXPERIMENTAL
Intervention: Genetic correlation between short and long sleep traits
Number of subjects: 445966
Study: 37770652

Group type: EXPERIMENTAL
Intervention: Garetosmab (activin A-blocking antibody)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 37770704

Group type: EXPERIMENTAL
Intervention: High-FN-risk chemotherapy regimen
Number of subjects: 3605

Group type: COMPARATOR
Intervention: Low and intermediate FN-risk chemotherapy regimens
Number of subjects: 3605
Study: 37770748

Group type: EXPERIMENTAL
Intervention: Different surgical approaches for total mesorectal excision (TME)
Number of subjects: 0
Study: 37770770

Group type: EXPERIMENTAL
Intervention: SPC R10/E10
Number of subjects: 305

Group type: COMPARATOR
Intervention: R10
Number of subjects: 305
Study: 37770865

Group type: EXPERIMENTAL
Intervention: 100 ppm hypochlorous acid mouthwash (MW)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 100 ppm hypochlorous acid mouthwash with periodontal flosser (MWPF)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 37770881

Group type: EXPERIMENTAL
Intervention: Mind-body and Art Therapies (MBATs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 150
Study: 37770889

Group type: EXPERIMENTAL
Intervention: Benralizumab treatment
Number of subjects: 204
Study: 37770908

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (8-10 mmHg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12-14 mmHg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-pressure laparoscopic cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-pressure laparoscopic cholecystectomy
Number of subjects: 100
Study: 37770944

Group type: EXPERIMENTAL
Intervention: VISA-G-Norwegian questionnaire
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Standardized Difference Change (SDC)
Number of subjects: 78
Study: 37770967

Group type: EXPERIMENTAL
Intervention: Health Dialogue (HD)
Number of subjects: 64
Study: 37771274

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: COVID-19
Number of subjects: 6263

Group type: COMPARATOR
Intervention: No COVID-19
Number of subjects: 6263

Group type: COMPARATOR
Intervention: COVID-19 survivors
Number of subjects: 6263
Study: 37771545

Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 4 weeks
Number of subjects: 23
Study: 37771546

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1632
Study: 37771697

Group type: EXPERIMENTAL
Intervention: Telehealth model for preanesthesia evaluation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training in videoconferencing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Themes identified from interviews
Number of subjects: 25
Study: 37772038

Group type: EXPERIMENTAL
Intervention: Identification of biomarkers of physical activity and health
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interventions aimed to improve quality of life through physical activity
Number of subjects: 180
Study: 37772064

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37772075

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37772282

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (6-48 mg daily)
Number of subjects: 228
Study: 37772419

Group type: EXPERIMENTAL
Intervention: CTCA + ICA
Number of subjects: 688

Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 688
Study: 37772436

Group type: EXPERIMENTAL
Intervention: PF-06817024 (10-1000 mg single intravenous doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06817024 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06817024 (repeat doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06817024 (single intravenous administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06817024
Number of subjects: 0
Study: 37772607

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37772663

Group type: EXPERIMENTAL
Intervention: Dynamic full-field optical coherence tomography (D-FFOCT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional processing and staining (hematoxylin-eosin)
Number of subjects: 152
Study: 37772721

Group type: EXPERIMENTAL
Intervention: TA-NRP Heart DCD
Number of subjects: 219

Group type: COMPARATOR
Intervention: SRR Super Rapid Recovery DCD
Number of subjects: 219

Group type: COMPARATOR
Intervention: Super Rapid Recovery non-heart DCD
Number of subjects: 219

Group type: COMPARATOR
Intervention: Donations after brain death
Number of subjects: 219
Study: 37772762

Group type: EXPERIMENTAL
Intervention: E6742, a specific antagonist of toll-like receptors 7/8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37772853

Group type: EXPERIMENTAL
Intervention: Initial microscopy evaluation of sputum samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: BioFire FilmArray Pneumonia Panel
Number of subjects: 0